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Maldigestion in cystic fibrosis (CF) affects approximately 90% of patients. As soon as pancreatic insufficiency is identified, enzyme
supplementation is prescribed even with breast fed infants. A pancreatic enzyme preparation developed particularly for infants, Creon® for
children (CfC), contains smaller granules to be administered with a dosing spoon (5000 lipase units per scoop).
Patients and methods: In a prospective, randomised, multi-centre study, 40 infants and toddlers received both CfC and Creon® 10000 (C10) for
two weeks each in a cross-over design. Dosing of pancreatic enzymes was continued as applied before the study. The primary endpoint was the
parents' treatment preference. Secondary endpoints included coefficient of fat absorption (CFA), clinical symptoms and safety parameters.
Results: 20 parents (51%) from the N=39 intent to treat sample preferred CfC, 9 (23%) preferred C10, and 10 (26%) had no preference The
applied doses led to a mean CFAwith similar results for both treatments (77.8% vs. 78.7%). Gastrointestinal symptoms were reported on a number
of study days, and some children had abnormal results for laboratory parameters of malabsorption. Safety and tolerability of the preparations were
good and all these parameters were comparable for both treatments.
Conclusion: Those parents who had a preference favoured CfC over C10. Both enzyme preparations improved malabsorption to a similar degree,
although the applied dosages could have been too low in some children reflected in a suboptimal CFA. These data support the use of CfC for
young patients with cystic fibrosis improving the daily care of this cohort detected mainly now through neonatal screening programmes.
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Cystic fibrosis (CF) is an autosomal recessive disease with a
wide spectrum of clinical manifestations. The most frequent
genetic defect in Europe, the F508del mutation, is almost
invariably associated with pancreatic insufficiency (PI) [1].
Most affected children are identified on clinical symptoms
during the first year of life, and pancreatic enzyme replacement
therapy (PERT) is initiated immediately after the diagnosis of PI
has been made [2,3] to allow an adequate growth. Implementa-
tion of CF neonatal screening programmes is increasing in
Europe [4,5]; it allows very early diagnosis around one month
of age.
Up to the mid 1980s, a fat-reduced diet was recommended
but the development of acid-resistant microsphere preparations
improved dramatically the stool fat loss in most patients [6,7]
even with high energy diets without any dietary restrictions.
For infants, experts recommend lipase doses of 400 to
800 units per gram ingested fat [2,7] (one quarter to one half of a
Creon® 10000 capsule (C10) per 120 ml feed of breast milk or
formula). For parents of young infants, it remains difficult to
administer such small doses. Creon® for children (CfC) was
particularly developed for those who require small amounts of
pancreatin or are unable to swallow capsules. Thus the
preparation is provided as a bulk of minimicrospheres in a
glass container, with a small spoon containing 5000 lipase units
per scoop. This device facilitates more exact dosing of lower
lipase units in small children.
The scientific literature contains very few data on objective
measurements of malabsorption in infants with CF or on the
efficacy and safety of enzyme preparations in this young age
group [8–10].
The present trial was primarily designed to assess whether
parents of infants prefer CfC over C10 on a lipase per lipase basis
and to determine the efficacy of the preparations on clinical
symptoms and laboratory measurements of malabsorption.
2. Patients and methods
2.1. Study design
This was a multi-centre, open, randomised, cross-over study
in CF infants with PI to compare two pancreatic enzyme
preparations, i.e. CfC and C10, with respect to their effect on
malabsorption and to the parents' preference of one drug over
the other (primary end point). The study was conducted at 13
sites in France between January and November 2004. Written
informed consent was obtained from parents or legal guardians.
The institutional review boards or ethical review committees
had approved the study protocol.
The study consisted of a two-week run in period, after which
children were randomised to treatment phase A to receive either
CfC (one spoon with 100 mg granules containing lipase 5000
Ph. Eur. Units, amylase 3600 Ph. Eur. Units, protease 300 Ph.
Eur. Units) or C10 (one capsule with 150 mg pancreatin labelled
lipase 10000 Ph. Eur. Units, amylase 8000 Ph. Eur. Units, and
protease 600 Ph. Eur. Units) for two weeks. The dose of lipasewas kept constant compared to PERT before the study. After
two weeks, a cross-over to treatment phase B was performed.
Compliance with medication was determined from the number
of dispensed and returned bottles or pots.
There were 4 study visits: 1) pre-study, 2) baseline and day 1
of treatment A, 3) end of treatment A, and 4) end of treatment B.
No dosing advice was given but patients remained on their
individual doses throughout the study. Doses were assessed in
run-in period and in the treatment phase. To ensure that the lipid
content of meals throughout the study was sufficient, the parents
were requested to add 1 soup spoon of sunflower oil to lunch
and dinner meals instead of their usual fat supplementation.
2.2. Patients
Patients were male or female between 6 and 36 months of
age with a proven CF diagnosis (two positive sweat tests or
mutation analysis). PI had been diagnosed by faecal pancreatic
elastase-1 concentrations (74%), stool fat excretion (3%), and a
combination of these and other tests (faecal chymotrypsin,
PABA test). Exclusion criteria were meconium ileus or other
conditions that had led to intestinal resection, severe con-
comitant diseases of other organ systems, any allergy to
pancreatin or other drugs, or suspected non-compliance of
subject or family.
2.3. Outcome measurements
The primary endpoint was the parents' preference of study
medication at Visit 4, assessed by answering the question:
“Which treatment did you prefer?” with one of the possible
answers 1) Treatment (medication) 1 was better than
Treatment (medication) 2, 2) Treatment 2 was better than
Treatment 1, or 3) no difference between Treatment 1 and
Treatment 2. In addition, parents were asked to give the
reason for their preference (practicability, symptomatology,
adverse event).
Secondary endpoints considered clinical symptoms and
objective measurements of malabsorption. Stools samples
were collected from day 12 to day 15 and from day 26 to 29,
fat excretion was determined from each 3-day stool collection
[11–13] at a central laboratory in Paris. Clinical symptoms
related to malabsorption were recorded on each day of the study
on diary cards with scales for stool frequency, stool consistency,
flatulence, and abdominal pain. Dietary questionnaires were
filled in from days 12 to 15 and from days 26 to 29. Fat as well
as energy intakes were calculated from the diaries in order to
calculate the coefficient of fat absorption (CFA) [13].
A dietician checked the accuracy of documented foods and
quantities, then data were entered into the database Nutrilog Pro
(Version 1.16, Nutrilog SAS, Ciqual, France 2001; Tables J.P.
Blanc — Aliments de marque 2004).
2.4. Statistical analyses
The primary efficacy analysis was based on the ITT sample
using Prescott's test [14] which takes into account the
Fig. 1. Parents' preference of enzyme preparation. Parents' preference per
treatment period for the two enzyme preparations CfC and C10.
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effect occurred.
The secondary efficacy variables were summarised descrip-
tively, both by treatment and by treatment sequence and period.
To assess the treatment effect, within-subject differences of
treatment phase B minus phase A were compared between the
sequences by exploratory tests (Wilcoxon–Mann–Whitney
test). This accounts for possible period effects, and no carry-
over effect was assumed.
Safety analysis used the safety sample which consisted of all
children who received at least one dose of study medication.
2.5. Determination of sample size
The following assumptions were made: 1) 20% of the
parents have no preference, 2) 60% prefer CfC, and 3) 20%
prefer C10. While applying Prescott's test with a level of
significance of £0.05 (two-sided) and using a t-test approxima-
tion, one would need 17 subjects per sequence to achieve a
statistical power of 80%. Since the exact test is slightly more
conservative than the approximation, 18 subjects per sequence
should complete both periods. To account for approximately
10% dropouts, 20 subjects per sequence were planned to be
randomizedrandomised.
2.6. Safety analyses
Adverse experiences were monitored and height, weight, and
vital signs were measured at each visit. A full physical
examination was conducted at visits 1 and 4.
3. Results
3.1. Patients
Forty infants participated in the study. 19 were randomised to
receive CfC and 21 to receive C10 during treatment phase A.
One subject was withdrawn due to adverse events during the
first treatment period, so that only 39 subjects were treated with
C10. With the exception of the withdrawn subject who missed
the last visit, all visits were attended. The intent-to-treat (ITT)
sample consisted of 39. Girls represented 56.4%. The age range
was 6 to 36 months with a mean of 19.2 months.
Before the study, 34 children (87%) had used C10 as PERT,
3 had used Creon® 25000, and 4 Creon® 5000. The mean (SD)
intake of lipase during the run-in period was 4488 (3039) lipase
units per kilogram and day (Table 1).Table 1
Mean (SD) patient demographic features and baseline characteristics
ITT population N=39
Age (months) 19.2 (9.5)
Gender (boys:girls) 17:22
Weight (kg) 10.1 (2.2)
Height (cm) 79 (0.9)
Lipase intake from PERT (units/kg/day) 4488 (3039)3.2. Primary end point: Parents' preference of formulation
75% of parents had a preference for one treatment over the
other: 51% preferred CfC, and 23% preferred C10. Parents
preferred CfC for practicability reasons (13 subjects) and/or
because their child had fewer symptoms (8 subjects). C10 was
preferred because children had less gastrointestinal symptoms
(4 subjects), because of practicability (3 subjects) or adverse
event (1 subject, bronchial infection). Four parents gave no
explanation and 2 mentioned 2 different reasons why they
preferred a certain enzyme preparation.
The remaining 10 parents (26%) liked either enzyme
preparation. (Fig. 1). Prescott's test for the comparison of
treatments gave p=0.066 which did not reach statistical
significance.
3.3. Secondary end points
3.3.1. Symptom diaries
On each study day, parents recorded symptoms of malab-
sorption in the subject's diary. The mean (SD) number of stools
per day was 2.4 (1.1) with CfC and 2.3 (1.0) during C10
therapy. On the majority of days, stool consistency were either
formed/normal (mean: 47.8% of days with CfC and 42.6% of
days with C10, respectively) or soft (41.4% vs. 41.1%). Hard or
watery stools were infrequent. Flatulence was a frequent event,
occurring in a mild form on 23.1% of days during CfC and on
34.9% of days during C10 treatment, and moderate flatulence
was observed on 9.0% and 7.3% of days, respectively. Children
were free from abdominal pain on 91% of days during either
treatment phase, and the percentage of days with mild or
moderate abdominal pain was 9% in both groups.
Overall, there were no clinically relevant differences
between treatments.
3.4. Calorie intake and stool fat analysis
Mean daily energy intake was 1100 kcal/day for a mean
body weight of 10.1 kg. Fat intake was about 40 g/day (Table
2), with comparable mean daily lipase intakes during the CfC
and C10 phases (3969 vs. 4310 U/kg/day). The mean faecal fat
excretion was higher than desired (9.2 and 8.3 g per day during
Table 2
Secondary efficacy parameters: Mean (SD) dietary intake and malabsorption
measurements
Creon® for children
(n=39)
Creon® 10,000
(n=39)
p value
Energy intake [kcal/day] 1105 (258) 1118 (304) 0.351
Fat intake [g/day] 42.8 (15.1) 41.9 (13.7) 0.727
Faecal fat [g/day] 9.2 (5.4) 8.3 (5) 0.119
Coefficient of fat absorption,
CFA [%]
77.7 (13.1) 78.7 (14.0) 0.351
Faecal energy content
[kcal/day]
138 (73.9) 135 (75.4) 0.419
Stool weight [g/day] 88.2 (45.3) 87.3 (49.5) 0.485
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78.7% during CfC and C10 treatment phases with some
interindividual ranges. No differences between the two enzyme
preparations were observed for all variables examined.
3.5. Safety
Determination of body weight, temperature, and pulse rate
showed no relevant differences between the two medications,
and the proportion of patients with adverse experiences was
comparable between groups. No loss of body weight was
observed with either treatment. In total, 17 subjects in each
treatment group showed adverse events, mainly upper
respiratory tract infections and gastrointestinal disorders.
Adverse events reported for more than 2 subjects for any
treatment was cough, toothache and nasopharyngitis as well as
bronchitis. In total, three patients in the CfC group experienced
related treatment emergent adverse events judged by the
investigator (abdominal pain, constipation, vomiting) one
patient in the C10 group (severe dermatitis diaper). Two
serious adverse events (SAEs) were observed; both considered
unrelated to study medication: a bronchial obstruction and
acute otitis during C10 treatment, and Pseudomonas aerugi-
nosa colonisation while receiving CfC. A toddler was
prematurely withdrawn after six days of CfC, he experienced
moderate abdominal pain and diarrhoea (possibly related to
study medication, described above) and vomiting (unlikely
related to study medication).
4. Discussion
Maldigestion due to PI is a characteristic feature of CF and the
majority of patients therefore require PERT [15] CfC was
developed particularly for infants and young children. A
calibrated spoon allows take out of 5.000 units of lipase per
dose out of a glass bottle containing pancreatinminimicrospheres.
The present study was primarily designed to evaluate how
parents assess the handling of the new preparation, CfC, in
comparison to the conventional C10 capsules, but also to assess
efficacy and safety in comparison to established therapy. Due to
the cross-over design of the trial, each parent tested both
preparations. More parents (51%) preferred CfC over the
conventional enzyme capsules (23%). However, more parents(26%) as anticipated did not express any preference thus the
result did not reach statistical significance (p=0.066).
For the average study participant with a body weight of
10 kg, a daily lipase dose of 40,000 units would translate into 4
capsules of C10 or 8 spoons of CfC to be administered
throughout 4 to 5 meals per day. Over half of the parents found
it easier to take out spoons of CfC from the granule container
rather than opening a capsule of C10. In infants it allows a better
handling of smaller enzyme doses, particularly with the high
numbers of feeding per day.
In addition to the primary objective of the trial, the results
provide important insights into the situation of PERT in infants
with CF. To our knowledge, this is the first original article
describing the extent of malabsorption as well as energy and fat
intakes in such a young patient population, being 3 years as the
minimal age of participants in other studies [8–10]. Malabsorp-
tion measurements in the present study suggest that many
infants had received suboptimal enzyme doses. During the
conduct of our trial, the dose of PERT had been kept constant in
each child and was the same as before the study. Mean lipase
doses were about 3969 and 4310 units per kg body weight and
day in the CfC and C10 phases, respectively. According to
current European [2] and North American [16] recommenda-
tions, upper limits for PERT are 10,000 units of lipase/kg/day.
Not surprisingly, the consequence of the relatively low
pancreatin doses was a substantial faecal loss of energy with a
mean fat excretion of 9 g per day during CfC (normal: b4.3 g/d
in infants and b3.1 g/d in children) [7]. These results underline
that faecal fat excretion measurements may be important tools if
clinicians wish to assess the appropriate PERT supplementation
in these young children. Our study demonstrated an insufficient
fat assimilation with the recommended PERT dosage, empha-
sizing the need for further studies aimed at reviewing the
present guidelines for PERT in infants.
The mean observed CFA of 79% in our patients was lower
than desired, although at the individual levels some patients had
normal fat absorption up to 98%. In randomised controlled
PERT studies, untreated CF patients on placebo had mean CFAs
between 45% and 55%, while adequate enzyme replacement
increased CFA to about 80% to 90% [7]. Some authors reported
even higher CFAs with sufficient pancreatin doses [10,17].
Young children achieve sufficient growth and weight gain more
easily when only small amounts of fat and energy are lost in the
stool. Increases in weight were larger during treatment with an
acid resistant enzyme preparation than after an uncoated
pancreatin formulation [18]. The present study with 4 weeks
duration demonstrated no loss of body weight with either
treatment but was too short to evaluate body weight develop-
ment for clinical relevance.
One of the aims of PERT is also to abolish unpleasant
gastrointestinal symptoms [7]. The clinical end-points of our
trial show some issues in well-being that might have been
caused by malabsorption. Parents recorded flatulence on up to
43% of study days and mild or moderate abdominal pain on 9%
of study days. One could speculate that after the occurrence of
fibrosing colonopathy in the early 1990s, physicians might have
been reluctant to prescribe larger enzyme doses. It may also be
18 A. Munck et al. / Journal of Cystic Fibrosis 8 (2009) 14–18that parents tended to underreport symptoms when asked during
routine clinic visits, while the daily records as part of a clinical
trial presented a more objective picture of abdominal pain and
distension. Since the study physicians were experienced
caregivers working at certified CF centres, we have no doubt
that these results are representative for other young children
with cystic fibrosis. From a clinicians' point of view, one of the
drawbacks of our study was that no attempt was made to
optimise the Creon® dose before randomisation. This would
certainly have been necessary if the primary focus of the study
had been the efficacy of pancreatin preparations for treating
malabsorption.
In conclusion, the results of the present study suggest that
parents of young CF children tend to prefer Creon® for children
over Creon® 10000 capsules. A subgroup of parents liked either
enzyme preparation, which is reassuring since older children
will need enzymes capsules later in their lives.
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